MCL-1 inhibition in cancer treatment

OncoTargets and Therapy

关键词: BCL-2;    BAX;    BAK;    apoptosis;    BH3 mimetics;   

DOI  :  

来源: DOAJ

【 摘 要 】

Weiguo Xiang,1 Chao-Yie Yang,1,2 Longchuan Bai1,21Department of Internal Medicine, University of Michigan Medical School, 2Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USAAbstract: Myeloid cell leukemia-1 (MCL-1), a member of antiapoptotic BCL-2 family proteins, is a key regulator of mitochondrial homeostasis. Frequent overexpression of MCL-1 in human primary and drug-resistant cancer cells makes it an attractive cancer therapeutic target. Significant progress has been made in the development of small-molecule MCL-1 inhibitors in recent years, and three MCL-1 selective inhibitors have advanced to clinical trials. This review briefly discusses recent advances in the development of small molecules targeting MCL-1 for cancer therapy.Keywords: BCL-2, BAX, BAK, apoptosis, BH3 mimetics

【 授权许可】

Unknown